Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants
- Author(s)
- Sachdeva, S; Mohmmed, A; Dasaradhi, PVN; Crabb, BS; Katyal, A; Malhotra, P; Chauhan, VS;
- Details
- Publication Year 2006-03-15,Volume 24,Issue #12,Page 2007-2016
- Journal Title
- VACCINE
- Publication Type
- Journal Article
- Abstract
- The C-terminal 42-kDa fragment of the merozoite surface protein-1 of Plasmodium falciparum (PfMSP-142) was expressed as a recombinant protein in Escherichia coli and purified to near homogeneity. We tested the immunogenicity of recombinant PfMSP-142 in three clinically acceptable adjuvants (Montanide ISA 720, alum and MF59) in mice and in rabbits. High antibody responses were obtained with two adjuvant formulations with IQGl being the predominant immunoglobulin isotype. Significant T-cell proliferation responses were also observed. Competitive enzyme linked immunosorbant assay (ELISA) showed the presence of both invasion and processing inhibitory antibodies in sera obtained from the immunized rabbits. Passive immunizations of mice with anti-PfMSP-1(42) IgG purified from the rabbit-sera were found to be protective against a parasite challenge with P. berghei/P. falciparum chimeric line (Pb-PfM19) that expresses Plasmodium falciparum MSP-1(19). These findings may be useful for the development of a malaria vaccine based on Plasmodium falciparum MSP-1(42). (c) 2005 Elsevier Ltd. All rights reserved.
- Publisher
- ELSEVIER SCI LTD
- Keywords
- C-TERMINAL FRAGMENT; MALARIA VACCINE CANDIDATE; HUMORAL IMMUNE-RESPONSES; GROWTH IN-VITRO; CD4(+) T-CELLS; AOTUS MONKEYS; DISULFIDE BONDS; ANTIGEN; 19-KILODALTON; ANTIBODIES
- Publisher's Version
- https://doi.org/10.1016/j.vaccine.2005.11.041
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2006-03-15 12:00:00